Why would'nt he be happy and confident? 11 months ago he was apologizing to stockholders for the perifosine debacle, biotech writers were posting Keryx obituaries, and he had only enough cash left to see one drug through that most analysts thought was a decent one but nothing more. Now he is overseeing a company that year to date has been the best performer of the Russell 3000, with a drug that may become a market leader and first of its kind in a much bigger one, and with $80 million cash in the bank. He has done a remarkable job this past year, and as a shareholder I could not be more pleased with the job he has done. Compare his body of work with that of the parasitic leadership of AEZS. Day and Night.